Olaratumab - CISMeF

Preferred Label : Olaratumab;

NCIt related terms : anti-PDGFR alpha monoclonal antibody IMC-3G3; anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3; IMC-3G3;

NCIt definition : A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.;

Alternative definition : NCI-GLOSS: A substance being studied in the treatment of glioblastoma (a type of brain tumor) that has come back. It binds to receptors for a protein called platelet-derived growth factor (PDGF). This keeps PDGF from binding to the cells. This may stop the growth of cancer cells and blood vessels that have the receptors for PDGF. It is a type of monoclonal antibody.;

UNII : TT6HN20MVF;

CAS number : 1024603-93-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1024603-93-7 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Lartruvo;

Molecule name : IMC-3G3; LY3012207;

Codes from synonyms : CDR0000648585; CDR0000648586; CDR0000648584; 367;

Details

Origin ID

C79825;

UMLS CUI

C2698152;

Automatic exact mappings (from CISMeF team)
- Olaratumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- Olaratumab (substance) [SNOMED CT concept]
- olaratumab [MeSH concept]
- olaratumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing olaratumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Olaratumab (substance) [SNOMED CT concept]
- Product containing olaratumab (medicinal product) [SNOMED CT concept]
- olaratumab [MeSH concept]
- olaratumab [MeSH Supplementary Concept]
- olaratumab [ATC Code]
Validated automatic mappings to BTNT
- olaratumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Antibody-Dependent Cellular Cytotoxicity [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Platelet-Derived Growth Factor Receptor Alpha [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients